AI Summary

A clinical trial in the Democratic Republic of Congo has enrolled more than 250 participants to test a drug that may prevent infection with the Bundibugyo strain of Ebola. The study targets the virus responsible for the country’s most severe outbreak, which has spread rapidly and for which no vaccine or approved treatment exists. Researchers view the enrollment as a critical step toward controlling the epidemic. The trial’s progress will determine whether the investigational drug can offer protection against this deadly strain.

AI summaries can be wrong sometimes—always verify important details using the source article.